RPRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Royalty Pharma PLC (RPRX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock demonstrates strong long-term growth potential, supported by favorable analyst ratings, robust financial performance, and positive hedge fund activity. While technical indicators are mixed, the overall sentiment and catalysts suggest this is a solid entry point for long-term investment.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), indicating a positive trend. However, the MACD is negative and expanding, suggesting short-term weakness. RSI is neutral at 67.796, and the stock is trading near its resistance levels (R1: 45.94, R2: 46.433).
Analysts have raised price targets and maintain Buy/Overweight ratings, citing strong Q4 results, long-term growth potential, and attractive royalty deals.
Hedge funds are significantly increasing their positions, with a 100.83% increase in buying activity last quarter.
The company has a strong financial position with $3.5B in capital for active deployment.
MACD indicates short-term bearish momentum.
No significant insider trading activity or recent congress trading data to further validate sentiment.
In Q4 2025, Royalty Pharma reported revenue growth of 4.78% YoY, net income growth of 2.88% YoY, and EPS growth of 6.38% YoY. Gross margin remained strong at 100%. These figures indicate steady and sustainable financial growth.
Analysts are highly positive on the stock. Recent upgrades include Morgan Stanley raising the price target to $61, Goldman Sachs to $51, and UBS to $49. Analysts highlight strong Q4 results, a catalyst-rich 2026, and long-term growth potential driven by synthetic royalties and a healthy royalty financing market.
